Researchers at Amsterdam UMC have developed a rapid and accurate diagnostic test for bacterial meningitis by measuring CRP protein levels in cerebrospinal fluid. Published today in The Lancet Regional Health Europe, this breakthrough could significantly reduce diagnosis time, enabling faster treatment for this life-threatening condition.
Bacterial meningitis, which kills one in six patients and leaves half of the survivors with lasting symptoms, is challenging to diagnose quickly. The new test addresses this by detecting elevated CRP levels in cerebrospinal fluid, a reliable indicator of the disease. Unlike current methods, which often delay treatment, this test provides results within 30 minutes using existing laboratory equipment.
Lead researcher Matthijs Brouwer emphasized the test’s practicality: “The existing infrastructure can measure CRP in cerebrospinal fluid, making it easy to implement.” The study confirmed that all patients with bacterial meningitis had elevated CRP levels, while few without the disease showed similar results. The test’s reliability was further validated in trials involving children and patients at Aalborg University Hospital in Denmark.
“Distinguishing bacterial meningitis from similar conditions has always been difficult. This test fills a critical gap,” said Brouwer. He added, “Its affordability, costing just three to five euros, makes it accessible for widespread use.”
The new CRP test, already in use at Amsterdam UMC, offers a fast, cost-effective solution for diagnosing bacterial meningitis. With its potential for broad adoption in hospitals worldwide, this innovation could save lives by ensuring timely treatment. Future research may explore its application in other infectious diseases.
Add comment